Regulator Requests Sample Clauses

The 'Regulator Requests' clause defines the obligations of the parties when a regulatory authority requests information, documents, or action related to the agreement. Typically, this clause outlines the process for responding to such requests, including timelines for notification, cooperation between the parties, and any confidentiality considerations. For example, if a government agency asks for records pertaining to the transaction, the parties must coordinate their response and ensure compliance with legal requirements. The core function of this clause is to ensure that both parties are prepared to handle regulatory inquiries efficiently and transparently, minimizing legal risk and ensuring compliance with applicable laws.
Regulator Requests. Supplier shall assist eBay in addressing any communications and abiding by any advice or orders from any Regulator empowered to enforce Applicable Data Protection Law ("Regulator Requests”).
View SourceView Similar (3)
Regulator Requests. With respect to its role as a processor of Customer, OCLC will provide reasonable assistance to Customer to address any communications and advice or orders from any Regulator relating to the Personal Data.
View SourceView Similar (2)
Regulator Requests. Phoenix will comply with Customer's reasonable request for internal or third party auditors access to the Phoenix Data Center, the Phoenix Banking System relating to Customer, and Customer's data and reports. Customer will provide Phoenix with reasonable notice of such audits, and will cause its auditors and staff to conduct such audits in a manner designed to minimize the disruption to Phoenix's operations.
View Source
Regulator Requests. At the trust's expense, the Trustee shall give the Regulator access to the trust's records and shall furnish to the Regulator such reports and information as the Regulator requests.
View Source
Regulator Requests. DailyPay shall use commercially reasonable efforts to assist the Company in addressing any communications and abiding by any advice or orders from government authorities relating to the Personal Data within the timeframe specified by the government authorities.
View Source

Related to Regulator Requests

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company’s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.